Cerebral ischemia (CI) can induce loss of hippocampal neurons, causing cognitive dysfunction such as learning and memory deficits. In adult mammals, the hippocampal dentate gyrus contains neural stem cells (NSCs) that continuously generate newborn neurons and integrate into the pre-existing networks throughout life, which may ameliorate cognitive dysfunction following CI. Recent studies have demonstrated that recombinant human thioredoxin-1 (rhTrx-1) could promote proliferation of human adipose tissue-derived mesenchymal stem cells and angiogenesis. To investigate whether rhTrx-1 also regulates hippocampal neurogenesis following CI and its underlying mechanisms, adult mice were subjected to bilateral common carotid arteries occlusion (BCCAO) to induce CI and treated with rhTrx-1 before reperfusion. Mice treated with rhTrx-1 showed shortened escape latencies in Morris water maze by 30 days and improvements in spatial memory demonstrated by probe trial test. Enhanced NSCs proliferation was observed at day 14, indicated by BrdU and Ki67 immunostaining. Doublecortin (DCX) þ cells were also significantly increased following rhTrx-1 treatment. Despite increases in BrdU þ /NeuN þ cells by day 30, the double-labeling to total BrdU þ ratio was not affected by rhTrx-1 treatment. The promotive effects of rhTrx-1 on NSCs proliferation and differentiation were further confirmed in in vitro assays. Western blot revealed increased ERK1/2 phosphorylation after rhTrx-1 treatment, and the ERK inhibitor U0126 abrogated the effects of rhTrx-1 on NSCs proliferation. These results provide initial evidence that rhTrx-1 effects neurogenesis through the ERK signaling pathway and are beneficial for improving spatial learning and memory in adult mice following global CI.
Introduction
Cerebral ischemic (CI) and neurodegenerative diseases can induce hippocampal neuron loss of varying severity which are pivotally implicated in the deficiencies of spatial learning and memory (Bendel et al., 2005; Chen et al., 2000; Hartman et al., 2005; West et al., 1994) . Although persistent progenitor cell proliferation and neurogenesis commonly follow ischemic periods in the forebrain subventricular zone and hippocampal dentate gyrus (DG), a phenomenon that has been well documented in rodent models, the definite role of neurogenesis following CI remains controversial.
Neurogenesis in response to ischemic neuron loss may be a result of neural stem cells (NSCs) participation in the endogenous repair processes of the adult mammalian brain (Okano et al., 2007) . New neurons have been detected in the injured area of previously ischemic tissues, where these new cells were functionally integrated into existing cerebral circuits (Lichtenwalner and Parent, 2006) . Conversely, neurogenesis has been suppressed using X-ray irradiation prior to bilateral common carotid arteries occlusion (BCCAO) in gerbil models, resulting in severe spatial learning and memory deficits following ischemia (Raber et al., 2004) . These findings underscore the importance of neurogenesis in functional recovery. Enhanced hippocampal neurogenesis also facilitates long-term potentiation and improves learning and memory (Abraham et al., 2002; Deng et al., 2010; Schmidt-Hieber et al., 2004) . Therefore, facilitation of endogenous neurogenesis may be a promising regenerative strategy for ischemic stroke treatment.
Both direct and indirect approaches have been developed to stimulate proliferation and neurogenesis, attenuate infarct volume, and improve neurological deficits in the ischemic stroke model. Thioredoxin (Trx), a 12-kD oxidoreductase enzyme containing a dithiol-disulfide active site, is a redox-sensitive molecule with pleiotropic cellular effects involved in regulation of proliferation, redox states, and anti-apoptosis (Mukherjee and Martin, 2008) . Two isoforms of Trx exist in mammalian cells. Cytosolic Trx-1, which can be translocated into the nucleus under certain circumstances, is the dominant form, and mitochondrial Trx-2 occurs relatively less frequently (Dunn et al., 2010) . Endogenous Trx-1 production is induced by ischemia of brain tissues, where it is responsible for alleviation of oxidative damage. Moreover, exogenously administered recombinant human Trx-1 (rhTrx-1) can penetrate the blood brain barrier and exert a neuroprotective effect, as demonstrated in the middle cerebral artery occlusion (MCAO) model (Hattori et al., 2004) . In addition to its role as an antioxidant, rhTrx-1 has also been reported to promote proliferation of human adipose tissue-derived mesenchymal stem cells and angiogenesis (Song et al., 2011; Welsh et al., 2002) .
While the neuroprotective role of rhTrx-1 on injured neurons is well-established, rhTrx-1 may also promote neurogenesis and facilitate long-term recovery following CI. In order to investigate this hypothesis, the current study applied the BCCAO mouse model to investigate the role of rhTrx-1 in neurogenesis and its potential effect on cognitive deficits in learning and memory following global CI. In addition, the mechanisms associated with rhTrx-1 were tentatively explored.
Materials and methods

Animals and experimental design
Male C57BL/6J mice weighing 25e30 g purchased from the Laboratory Animal Center of the Fourth Military Medical University (Shaanxi, China) were used in the current in vivo studies. All experimental protocols complied with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH). All experiments were also conducted in accordance with the Fourth Military Medical University Committee on Animal Care.
Mice were provided ad libitum access to food and water, and mice were housed in a temperature-controlled room with 12 h lightedark cycles. Experimental procedures for in vivo studies are described in Fig. 1 . Briefly, mice were randomized into 3 groups: the sham-operated group, the cerebral ischemia plus vehicle (CI þ Vehicle) group, and the cerebral ischemia plus rhTrx-1 (CI þ rhTrx-1) group. Mice of each group were then equally divided into two subgroups for cognitive function evaluation and neurogenesis detection, respectively.
Mice of the CI þ rhTrx-1 group were subjected to transient BCCAO for 20 min and intraperitoneal (i.p.) administration of rhTrx-1 containing 3 mg/kg of the cytosolic form of Trx (Sigma-Aldrich, St. Louise, MO) 10 min before reperfusion, according to the previously published method (Hattori et al., 2004; Tao et al., 2006) . The CI þ Vehicle group was simultaneously treated with similar BCCAO and i.p. administration of an equal volume of a 0.1 M phosphate buffered saline (PBS) solution as an inert vehicle (pH 7.4).
For neurogenesis analysis, mice were treated with daily 100 mg/ kg i.p. injections of 5-bromo-2 0 -deoxyuridine (BrdU; SigmaAldrich, St. Louis, MO) for 4 consecutive days, during the peak of cell proliferation, or from days 9e12 after rhTrx-1 or vehicle treatment, according to the previously reported method (Bernabeu and Sharp, 2000; Liu et al., 1998) . Mice of the sham-operated group also underwent i.p. injection of BrdU following sham surgeries. All the mice were sacrificed by days 14 and 30 and tissues were collected for further immunohistochemical study. Behavioral tests were performed 30 days after ischemia. NSCs were harvested from the fetal brain of pregnant Sprague-Dawley rats under deep anesthesia induced by treatment with 300 mg/kg i.p. chloral hydrate between embryonic days 14.5 and 16.5.
Transient forebrain cerebral ischemia
Mice were anesthetized with 2% isoflurane using a facemask, and CI was induced by transient BCCAO for 20 min, as described previously (Homi et al., 2003; Tajiri et al., 2004; Wu et al., 2001) . Sham-operated animals were treated with the same surgical procedure, with the exception of occlusion. A PeriFlux System 5000 laser Doppler flowmeter (Perimed, Stockholm, Sweden) was used to measure regional cerebral blood flow (rCBF) from the start of anesthetic induction to 5 min after reperfusion (Olsson et al., 2004; Yoshioka et al., 2011 ). In the current experimental model, only results from mice with a mean CBF successfully reduced to 10% of the pre-ischemic value were used in subsequent data analysis. Rectal temperature was maintained at 37.5 AE 0.5 C with a heating lamp until mice were revived.
Arterial blood gas determination
Left femoral arterial catheters were placed in separate groups of sham, CI þ Vehicle and CI þ rhTrx-1 groups (n ¼ 5 in each group) to determine the arterial blood gas (Table. 1). About 0.2 ml of blood Fig. 1 . Graphic presentation of the experimental protocol. The mice brain ischemia model was induced by BCCAO for 20 min. Experimental mice were randomized to receive either vehicle (0.1 M PBS, pH 7.4; i.p.) or an equal volume of rhTrx-1 (3 mg/kg; i.p.) 10 min before reperfusion. BrdU (100 mg/kg; i.p) was administrated daily for 4 consecutive days from 9 to 12 days after ischemia, and mice were then sacrificed for neurogenesis assays at 14 and 30 days post-ischemia. Behavioral testing was conducted 30 days after ischemia. Sham-operated animals were also injected with BrdU after sham surgeries and subjected to behavioral testing prior to sacrifice. per mice was taken via femoral artery at the onset of BCCAO and reperfusion. After the final blood sample taken, blood gas was immediately analyzed (Rapidlab 1260, Bayer HealthCare, Uxbridge, United Kingdom).
Behavioral tests
Experimental C57BL/6J mice were subjected behavioral tests 30 days after ischemia. To minimize potential stress-related effects from previous behavioral performance testing, mice were first tested in the open field and then in the water maze, according to the previously published method (Raber et al., 2004) .
Open-field test
Spontaneous locomotor activity was evaluated using an openfield test. Mice were individually placed in the center zone of an open field apparatus (50 Â 50 Â 40 cm). All movements were traced, and data were collected by video for 15 min after a 2 min habituation period. Total distances traveled and percentage of time spent in the 30 Â 30 cm square center zone of the apparatus was analyzed by an automatic analyzing system (DigBehav, Jiliang Co. Ltd., Shanghai, China) (Miki et al., 2009; Miyakawa et al., 2001) . The apparatus was cleaned with water after each trial.
Morris Water Maze (MWM) test
MWM was employed to assess mouse spatial learning and memory according to previously published methods (Morris, 1984; Rehni et al., 2009 ). The maze consisted of a large circular pool (150 cm in diameter, 45 cm in height, filled to a depth of 30 cm with water at 28 AE 1 C). Water was made opaque with a white dye. A painted white platform (10 cm 2 ) was submerged and placed in the center of the target quadrant at 1 cm below the surface of water, providing the escape area. The position of the platform was maintained unaltered throughout the training session. Mice were allowed 4 training trials per day for 5 consecutive days. During each trial, mice were allowed to start from a random location in each of 4 quadrants. Mice were placed in a starting position in which its head was facing the wall, and the hidden platform was maintained in a fixed location. Each mouse was allowed a maximum of 60 s to find the submerged platform and rest for 30 s. If the mouse failed to find the hidden platform within 60 s, it was manually guided to the platform and allowed to rest for 30 s. The escape latency to find the hidden platform and the total path length to the platform were recorded. On the day 6, mice were subjected to a 60 s probe trial in which the platform was removed.
The percentage of time spent in the target quadrant was considered to reflect memory retention, as previously described (Lai et al., 2007) . A digital video camera was positioned directly above the water maze, enabling full collection of swim activity in the different quadrants, and the data feed was attached to a computer using DigBehav System (Jiliang Software Co., Shanghai, China) software (Peng et al., 2010) .
Tissue preparations and immunohistochemistry
Mice were subjected to deep anesthesia with 300 mg/kg i.p. chloral hydrate and treated with saline followed by a cold 4% paraformaldehyde during transcardiac perfusion. Brain tissues were then extracted and post-fixed in 4% paraformaldehyde overnight at 4 C. After successively infiltrated with in 0.1 M PBS containing 20% and 30% sucrose overnight, coronal sections in 12 mm thicknesses were cut and stored at À20 C until use. For BrdU immunohistochemistry, brain tissue sections were incubated in HCl (1 N) for 40 min at 45 C to break open the DNA structure of the labeled cells, as previously described (Fournier et al., 2012; Wojtowicz and Kee, 2006) . Immediately after the acid wash, borate buffer (0.1 M) was added to the cells. All sections were then incubated in a blocking solution for 1 h prior incubation with 1:100 rat-anti-BrdU (Abcam, USA) diluted in PBS at 4 C for 48 h. Following incubation with the primary antibody, these sections were treated with 1:100 biotinylated goateanti-rat (Vector, USA) at room temperature for 2 h followed by treatment with 1:1000 rhodamineeavidin D anti-mouse IgG (Vector, USA) at room temperature for 2 h. For Ki67 (the marker of cell proliferation) and DCX (donblecortin, the marker of developing, immature neurons) staining, sections were first treated with 1:1000 anti-rabbit Ki67 (Abcam, USA) and 1:2000 anti-rabbit DCX (Abcam, USA) antibodies at 4 C overnight. After washing in PBS, sections were then incubated in 1:500 Alexa Fluor 488-conjugated donkey anti-rabbit (Invitrogen, USA) and 1:500 Alexa Fluor 594-conjugated goat anti-rabbit (Invitrogen, USA) secondary antibodies at room temperature for 4 h. For double immunostaining, sections were incubated with rat anti-BrdU first, as described previously. After treatment with a biotinylated goateanti-rat and Rhodaminee avidin D, these sections were washed in PBS and treated with 1:100 mouse anti-NeuN (Chemicon, USA) at 4 C overnight followed by treatment with 1:500 Alexa Fluor488-conjugated anti-rat IgG (Invitrogen, USA) at room temperature for 4 h. Finally, sections were incubated with Hochest 33342 for 10 min at room temperature to stain cell nuclei.
Cell culture and drug administration
Embryonic brains between E14.5 and E16.5 were dissected under a stereomicroscope, and single cell suspensions from the hippocampus were obtained by mechanical dissociation. Cell suspensions were primarily plated at a density of 5 Â 10 5 cells/ml in 25 cm 2 Corning (USA) cell culture flasks using serum free Dulbecco's modified Eagle's medium (DMEM)/F12 medium containing 20 ng/ml bFGF (human recombinant, Peprotech, 100-18B, USA), 20 ng/ml EGF (rat recombinant, Peprotech, 400-25, USA), B-27 and N-2 supplement (Gibco, USA), and penicillin and streptomycin. The resultant neurospheres were harvested and mechanically dissociated to produce a single cell suspension for replating every 6e7 d. All experiments were performed during the second or third passage, after which single cells were resuspended. Cells were seeded onto plates or cover clips for 1 h, and rhTrx-1 was added to the culture medium at variant concentrations. The ERK signaling pathway was inhibited by adding 4 mM of U0126 (Sigma-Aldrich, USA) to the medium 0.5 h prior to rhTrx-1 administration.
Immunocytochemistry
To verify the identity of NSCs, neurospheres or single cells were collected and fixed in 4% paraformaldehyde. Frozen sections of the neurospheres and single cells on the cover slips were incubated with a mouse anti-nestin antibody (1:500, Abcam, Hong Kong) overnight at 4 C. Immunolabeling was visualized by an anti-mouse Alexa Fluor 594-conjugated secondary antibody (1:500, Invitrogen).
Proliferation assay was performed after NSCs were incubated with rhTrx-1 for 2 d. rhTrx-1-treated neurospheres were labeled with 10 mM BrdU for 2 h and then dissociated into single cells and plated onto poly-L-lysine coated cover clips at a concentration of 2 Â 10 4 cells per well in 24-well plates. After a 6 h attachment period, cells were fixed in 4% paraformaldehyde for 45 min. The fixative was then removed, and cells were incubated in HCl (1 N) for 30 min at 37 C to break open the DNA structure of the labeled cells.
Immediately after acid washing, cells were incubated with borate buffer (0.1 M) for 10 min and processed for BrdU staining. In Ki67 staining experiments, cells were plated onto cover slips at a density of 2 Â 10 4 cells per well in 24-well plates and treated with rhTrx-1.
For immunostaining, cells were incubated at 4 C overnight in PBS supplemented with 1% bovine serum albumin (BSA) and 0.3% Triton-X100 and either rat-anti-BrdU (1:100, Abcam, USA) or rabbit anti-Ki67 antibody (1:1000, Abcam, USA). Following incubation with rat anti-BrdU, cells were treated with 1:100 biotinylated goat anti-rat IgG (Vector, USA) at room temperature for 2 h followed by treatment with 1:1000 rhodamineeavidin D anti-mouse IgG (Vector, USA) at room temperature for 2 h. Following incubation with Ki67, cells were incubated with a fluorophore-conjugated secondary antibody (Alexa Fluor 488, 1:500, Invitrogen, USA) for 2 h at room temperature. Cells were further counter-stained using 50 mg/ml propidium iodide (PI, SigmaeAldrich, USA) or DAPI for nuclei staining. BrdU-labeled and Ki67-positive cells were counted and normalized to the total cell count. NSCs were phenotyped 7 days after rhTrx-1 treatment by protein marker expression. Cells were seeded on poly-D-lysine-coated cover clips at a density of 3 Â 10 4 cells/well in DMEM/F12 medium containing 4% fetal bovine serum (SigmaeAldrich, USA) and treated with rhTrx-1 for 7 d. After fixation, cells were incubated at 4 C overnight with the primary antibodies composed of 1:500 mouse anti-Tuj1 (the marker of differentiated neurons; SigmaeAldrich, USA) and 1:2000 rabbit anti-GFAP (the marker of differentiated astrocytes; Millipore, USA) diluted in blocking reagent and then incubated with 1:500 secondary antibodies (Alexa Fluor 488 or Alexa Fluor 594, Invitrogen, USA) for 2 h at room temperature. Finally, cells were incubated with DAPI to stain the nuclei.
Western blot
Cells were collected and lysed with SDS-PAGE sample buffer composed of 62.5 mM TriseHCl, 2% w/v SDS, 10% glycerol, 50 mM DTT, and 0.1% w/v bromphenol blue. Insoluble materials were separated by centrifugation at 12,000 g for 10 min, and the supernatant was heated at 100 C for 10 min and then cooled on ice for 30 min. Electrophoresis was conducted by SDS-PAGE by using 10% polyacrylamide in accordance with routine protocols. Then the proteins in PAGE were transferred onto nitrocellulose membranes and blocked in blocking solution containing 5% defatted milk powder, 0.1% Tween-20 in TBS for 1 h at room temperature with gentle shaking. After being washed in TBS 3 times for 8 min each, the following primary antibodies were used for incubation overnight at 4 C: 1:2500 rabbit anti-pERK1/2 (Cell Signaling, USA), 1:2500 rabbit anti-ERK1/2 (Cell Signaling, USA), 1:1000 mouse anti-pAkt (Cell Signaling, USA), 1:1000 total Akt (Cell Signaling, USA), 1:1000 rabbit anti-Tuj1 (SigmaeAldrich, USA), 1:5000 rabbit anti-GFAP (Millipore, USA), and 1:10000 rabbit anti-GAPDH antibody (SigmaeAldrich, USA) as a loading control. All membranes were then washed 3 times in TBS and incubated with peroxidaseconjugated goat anti-rabbit IgG or peroxidase-conjugated goat anti-mouse IgG in TBST for 1 h. Immunoreactive bands were detected using enhanced chemiluminescence (ECL; Amersham, UK) by Tukey post-hoc test and expressed as means AE S.E.M. from six independent animals (n ¼ 6). # P < 0.05, ## P < 0.01 vs sham-operated group; *P < 0.05, **P < 0.01 vs CI þ Vehicle group. according to previous methods (Brown et al., 2003; Maysami et al., 2008) . Total numbers of DCX-labeled cells in the DG were counted under light microscopy for each mouse. DCX þ neurons and granule cells were counted throughout the section thickness, excluding cells in the uppermost focal plane (Fuss et al., 2010; Naylor et al., 2008) . For quantification of double-labeled cells, the percentage number of new neurons (60 BrdU þ cells per mouse) was assessed using confocal microscopy. The percentages of BrdU þ /NeuN þ cells to the absolute number of BrdU þ cells was calculated to provide a ratio of newly generated neurons (Jiang et al., 2005) . In the in vitro experiment, BrdU-, Ki67-, Tuj1-, and GFAP-labeled cells were counted. Results were expressed as a percentage to the total cells indicated by PI or DAPI staining. At least 3e5 independent experiments were performed for each assay.
All data were analyzed using GraphPad Prism (GraphPad, USA) software. Histological data as well as relevant data from in vivo and in vitro assays were analyzed by one-way ANOVA followed by Tukey post-hoc testing in order to investigate the differences between sham, CI þ Vehicle, and CI þ rhTrx-1 groups at corresponding time intervals. Behavioral testing data were analyzed by repeated-measure two-way ANOVA, and probe trail testing data were analyzed by one-way ANOVA followed by Tukey post-hoc testing. Results were presented as mean AE standard error of the mean (SEM). A P-value of less than 0.05 was considered significant (P < 0.05), and a P-value of less than 0.01 was considered highly significant (P < 0.01).
Results
rhTrx-1 ameliorated spatial learning and memory deficits induced by ischemia
In the Morris Water Maze test, long latent period were initially required to find the platform for all mouse subjects, though this time decreased with progressive trial number. Sham-operated and CI þ rhTrx-1 groups showed no significant differences in tasklearning abilities and similar latency reduction rates (P > 0.05). Mice in the CI þ Vehicle group, however, required increased time to locate the submerged platform compared with times in the rhTrx-1 and sham groups for each training day in MWM testing. Consistent with these findings, two-way ANOVA indicated that group and day exerted significant effects on escape latency. At test day 1, CI þ Vehicle mice required longer times to find the platform relative to the CI þ rhTrx-1 group; however, no statistical difference was observed (P > 0.05). By days 2e4, the time required to find the platform in the CI þ Vehicle group was notably longer than those in both the sham-operated and CI þ rhTrx-1 groups ( Fig. 2A , P < 0.01 at day 1 and 3; P < 0.05 at day 4) groups. Swimming speed during the test was also evaluated and analyzed by two-way ANOVA, demonstrating no group or day effects on swimming speed ( Fig. 2B , P > 0.05). In the probe trial test, both sham-operated and CI þ rhTrx-1 group mice appeared to have learned the task, demonstrating superior ability to remember the platform location compares to vehicle-treated mice. This effect was evidenced by significantly longer periods of time spent in the target quadrant in the sham-operated and CI þ rhTrx-1 groups compared to the CI þ Vehicle group (Fig. 2C , P < 0.05).
To assess whether reduced activity levels could have contributed to impairments in MWM performance following ischemia, experimental mice were tested for open-field activity. In the open field test, no significant difference in horizontal distance of travel in analyzed by one-way ANOVA, followed by Tukey post-hoc test and expressed as mean AE S.E.M. from 5 wells per treatment condition. *P < 0.05, **P < 0.01 vs Vehicle group. the chamber was observed among the three groups ( Fig. 2D , P > 0.05). In addition, the number of entries to the central zone of the open field was recorded in order to assess mouse anxiety level. No significant difference was observed in center zone time for any group ( Fig. 2E , P > 0.05).
rhTrx-1 promoted ischemia-induced neurogenesis in DG
To investigate the effect of rhTrx-1 on proliferation of the neural stem cells following forebrain ischemia, the cells incorporated with BrdU and those stained with Ki67 in the DG were counted (Fig. 3A) . At post-ischemic day 14, the number of BrdU þ cells increased approximately 1.5-fold in the CI þ Vehicle group compared with the sham-operated group ( Fig. 3B ; P < 0.05). In addition, administration of rhTrx-1 significantly increased the number of BrdU þ cells compared with the CI þ Vehicle group (P < 0.01). Similarly, the CI þ Vehicle group showed increased numbers of Ki67 þ cells ( Fig. 3B ; P < 0.05) and this number reached approximately 2-fold in CI þ rhTrx-1 group (P < 0.01). DCX expression was used to estimate cycling precursors of neuronal lineage as well as maturing young granule cells (Fuss et al., 2010 ) (Couillard-Despres et al., 2005 . The CI þ rhTrx-1 group demonstrated a significant increase in the number of DCX þ cells in the DG (Fig. 3C, D ; P < 0.01).
To estimate the effect of rhTrx-1 on the differentiation of NSCs, double labeling of BrdU and NeuN was performed 30 days after ischemia (Fig. 3E) . The number of BrdU þ cells in the CI þ rhTrx-1 group was much larger than that observed in the CI þ Vehicle group ( 
rhTrx-1 enhanced proliferation of cultured NSCs
To investigate the direct effects of rhTrx-1 on NSCs and to study the underlying mechanism, in vitro study was also conducted. As shown in Fig. 4C , neurospheres and single cells expressed nestin, a marker of NSCs. After treatment with different concentrations of rhTrx-1 for 48 h, the percentage of BrdU labeled cells was higher in 10 and 100 mg/ml rhTrx-1 treatments compared to the vehicle group, while less BrdU positive cells were seen in the 500 mg/ml treated group (Fig. 4A, D ; P < 0.01). The results of Ki67 staining also revealed that rhTrx-1 promoted proliferation of NSCs at concentrations of 10 and 100 mg/ml, but inhibited proliferation at 500 mg/ ml ( Fig. 4B, E ; P < 0.01).
rhTrx-1 promoted NSCs differentiating into neurons
After treatment with rhTrx-1 for 7 days, expression of Tuj1 and GFAP were examined (Fig. 5A) . Immunocytochemical results revealed that the ratio of differentiated neurons was higher in groups treated with both 1 mg/ml (13.51%) and 10 mg/ml (18.08%) rhTrx-1 compared with the vehicle group (7.21%) ( Fig. 5C ; P < 0.05 at 1 mg/ml, P < 0.01 at 10 mg/ml). Western blot analysis showed that Tuj1 expression of NSCs in the 10 mg/ml treatment group was increased approximately 1.5-fold compared to the vehicle group ( Fig. 5D , P < 0.05). The ratio of GFAP positive cells and the expression of GFAP in NSCs were decreased when cells were incubated in 10 mg/ml of rhTrx-1 (Fig. 5C, D ; P < 0.05).
Neurogenesis enhanced by rhTrx-1 was inhibited by U0126
Both MEK/ERK and PI3K/Akt signaling pathways have been implicated in the mechanism of proliferation and neurogenesis of NSCs. The activation of these pathways during rhTrx-1 treatment and subsequent induction of proliferation and neurogenesis were explored using a 10 mg/ml rhTrx-1 treatment to further study this mechanism. Expression of phosphorylated ERK1/2 began to increase at 2 h, maintain a high level to 48 h after rhTrx-1 administration ( Fig. 6A ; P < 0.05 at 2 h, P < 0.01 at 24 h and 48 h). The levels of phosphorylated Akt did not significantly change after NSCs incubation with rhTrx-1 (P > 0.05). Western blot analysis of the protein sample, extracted from NSCs cultured for 48 h in proliferation medium revealed that pretreatment with the inhibitor of ERK1/2 U0126 inhibited the elevation of the phosphorylated ERK1/ 2 induced by rhTrx-1 ( Fig. 6B ; P < 0.01). Furthermore, U0126 suppressed increases in the ratio of BrdU labeled cells in the rhTrx-1 treated group ( Fig. 6C ; P < 0.05). Also, co-administration with U0126 decreased the percentage of neuronal differentiation ( Fig. 6D , P < 0.05) compared to levels observed in the rhTrx-1 group (P < 0.01).
Discussion
The prominent effects of rhTrx-1 treatment for improving spatial learning and memory impairments in adult mice subjected to global CI were demonstrated in the present study. Moreover, rhTrx-1 was demonstrated to promote neurogenesis in the DG, indicating that rhTrx-1 potentially plays a role in the induction of neurogenesis and the facilitation of cognitive recovery following ischemia of cerebral tissues in mice. The in vitro study of rhTrx-1 in mice further demonstrated that the treatment also has the ability to enhance NSC proliferation and differentiation to neural cells. Furthermore, the ERK signaling pathway participated in stimulated neurogenesis.
The hippocampus is associated with the processes of learning and memory in mammals (Auer et al., 1989; Squire, 1992) . In previous studies, it has been reported that 20 min of BCCAO treatment can obliterate more than 50% of all hippocampal CA1 neurons (Zhang et al., 2010) , contributing to significant learning impairments visualized in mice by MWM testing (Block, 1999; Raber et al., 2004) . With rhTrx-1 treatment, functional impairments resulting from such ischemic periods were significantly improved at postischemic day 30, as demonstrated by both training and probe trail testing results in the current study. These results suggest that exogenous administration of rhTrx-1 may facilitate persistent cognitive recovery following CI. Notably, mice treated with rhTrx-1 displayed equivalent swimming abilities during MWM testing and equivalent locomotion activity during open-field testing compared to other groups. Therefore, the functional impairments in ischemic animals during the MWM testing may be partially or completely caused by deficits in task learning. These tests do, however demonstrate that these deficits are not related to limitations of normal motor functions. A considerable degree of neurogenesis from endogenous precursors has been reported to occur following CI in the adult mammalian brain, as documented in various rodent models (Jin et al., 2001; Kee et al., 2001; Liu et al., 1998) . This observation suggests the possibility that neuronal cells genesis might provide an alternative mechanism for post-ischemic functional recovery (Arvidsson et al., 2002; Carmichael, 2006; Hermann and Chopp, 2012) . Neurogenesis occurs in 2 sites in the brain of adult mammals, the SGZ and the subventricular zone (SVZ) of the lateral ventricle. These regions comprise the entire capacity of neurogenesis throughout an animal's life (Cameron and McKay, 2001; Kempermann et al., 2004) . The survival rate of adult neural precursor cells in the ischemic brain, however, is very poor. In fact, only a small percentage of these cells successfully differentiate into new neurons (Zhang et al., 2004 (Zhang et al., , 2011 . Thus, numerous therapeutic intervention strategies have been designed with the goal of promoting endogenous neurogenesis and subsequent survival of implanted neural stem cells (Bartolini et al., 2011; Wei et al., 2012) . The current results demonstrate that administration of rhTrx-1 exerted significant proliferative effects on hippocampal precursors. Combined with previous reports, these findings may indicate that the cellular mechanisms underlying the protective effects of rhTrx-1 may vary during different reperfusion stages following ischemia. In early stages following ischemia, rhTrx-1 may reduce apoptotic death, thus exerting neuronal protection (Ma et al., 2012) . During late stages, rhTrx-1 may increase generation and survival of new neurons in the hippocampus. In the adult mouse hippocampus, newly generated neural cells are functionally integrated into the hippocampal circuitry by 4 weeks and display passive membrane properties, action potentials, and functional synaptic inputs similar to those found in mature dentate granule cells (van Praag et al., 2002) . Considering these observations, functional recovery at 4 weeks after rhTrx-1 administration may be attributable to the neurogenesis promotion effects of rhTrx-1. The current histological and Western blot results also confirm that neural cell proliferation was markedly increased after administration of 10 mg/ml rhTrx-1. Similarly, differentiation of NSCs into neurons was also stimulated in cultured cells in the present study. However, we noticed that administration of much higher concentration of rhTrx-1 (500 mg/ ml) showed an inhibiting action on the proliferation of cultured neural stem cells inversely, indicating a bell shape effect of rhTrx-1 on proliferation. Interestingly, it has been reported that the chemotactic effect of rhTrx-1 on human PMNs and T cells is also manifested as a typical bell-shaped doseeresponse curve (Bertini et al., 1999) . Based on these data, it may be tentatively concluded that rhTrx-1 facilitates cell repair in hippocampus through stimulation of neurogenesis by endogenous progenitor cells, thus improving behavioral recovery. Although these results provide evidence supporting the hypothesis that neurogenesis contributes to the neuroprotective effects of rhTrx-1 following ischemic injury in brain tissues, the possibility that other potential effects of rhTrx-1 are also involved in the recovery of behavior cannot be excluded.
Both the MEK/ERK and PI3K/Akt signaling pathways participate in neurogenesis following cerebral ischemia (Kilic et al., 2006; Shioda et al., 2009 ). The ERK signaling cascade is reported to control the proliferation of multiple cell types, including neural stem/ progenitor cells, especially in response to growth factor treatment (Li et al., 2001; Wang et al., 2009) . The current study revealed that administration of rhTrx-1 increased the level of activated ERK1/2. These findings were confirmed by abolishment of rhTrx1-induced proliferation when the ERK signaling pathway was blocked by U0126, also dramatically reducing expression of the neuronal marker Tuj1. Although accumulating evidence supports the effect of the PI3K/Akt signaling pathway in cell cycle regulation (Liang and Slingerland, 2003) , stem cell self-renewal, and neuronal cell number and composition (Easton et al., 2005; Tschopp et al., 2005) , no significant changes in pAkt level were reported in mice treated with rhTrx-1. Cumulatively, these data suggest that the ERK signaling pathway is necessary for regulation of proliferation and differentiation in NSCs treated with rhTrx-1. The potential role of rhTrx-1 in the activation of the ERK signaling pathway, however, was not determined by this study. Recent evidence has demonstrated that vascular endothelial growth factor (VEGF) has a broad range of neurotropic and neuroprotective effects in the central nervous system (CNS) (Ruiz de Almodovar et al., 2009) , where it stimulates self-renewal of both embryonic and adult NSCs through the MEK/ ERK and PI3K/Akt signaling pathways (Fournier et al., 2012; Shen et al., 2004) . Conversely, Trx1 is able to regulate VEGF levels in both embryonic and adult neural stem cells under either normoxic or hypoxic conditions, thus promoting angiogenesis by acting on hypoxia inducible factor 1a (HIF-1a) (Welsh et al., 2002) . Therefore, rhTrx-1 is possibly both a neurogenic and angiogenic factor, promoting neurogenesis through the ERK signaling pathway in the CNS.
Neural stem cells play a pivotal role in self-renewal, potentially differentiating into various different cytotypes (Doe, 2008; Shimazaki and Okano, 2008) . Neurogenesis in the SGZ has been shown to be related to exercise, spatial learning, and memory (Gould et al., 1999; van Praag et al., 1999) . Moreover, active neurogenesis is crucial for injury repair to morphological changes in the hippocampus caused by neuron loss associated with either ischemia or neurodegenerative diseases, such as Alzheimer's disease, rheumatoid arthritis and stroke, or trauma (Ramirez-Ruiz et al., 2005; Wang et al., 2001) . Therefore, development of new drugs and treatments to promote neurogenesis may enable replenishment of lost neurons, providing a promising strategy for treatment of these neurodegenerative diseases. In fact, several neuronal growth factors have been demonstrated to promote neurogenesis, as previously described. In addition, recent evidence has demonstrated the importance of the relationship between neural stem/progenitor cells and vasculature (Louissaint et al., 2002; Palmer et al., 2000; Shen et al., 2004) . Cumulatively, these findings provide compelling evidence for the coordination of angiogenesis and neurogenesis in the CNS; however, clinical application remains limited by low bioavailability and the limited capacity of most drug therapies to cross the bloodebrain barrier. Trx1 is a small redox protein present in many organisms, where it plays a role in important biological processes and endothelial cells angiogenesis. Moreover, Trx1 crosses the bloodebrain barrier. Thus, rhTrx-1 exhibits favorable pharmacokinetics and a good safety profile for human applications, making it a prime candidate for angiogenesis and neurogenesis mediation in developing and adult brains.
The current study clearly demonstrates that rhTrx-1 is effective in promoting neurogenesis in the dentate gyrus and facilitating cognitive recovery following CI in adult mice. Additionally, the underlying mechanism of rhTrx-1 in neurogenesis was confirmed to be mediated by the ERK signaling pathway. These results suggest that rhTrx-1 may be a potential agent for the clinical treatment of ischemic injury in brain tissues.
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